跳至主要内容
临床试验/NL-OMON21762
NL-OMON21762已完成不适用

Effects of the co-administration of budesonide on the plasma exposure of cabazitaxel (Jevtana®) in castrate resistant prostate cancer patients.

Erasmus Medical Center, Daniel den Hoed Cancer Center0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
18

研究概览

简要总结

ieuweboer et al. Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: A randomized open-label multicenter phase II study. Clin Cancer Res. 2016 Oct 4 [Epub ahead of print]

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Metastatic castrate resistant prostate cancer (mCRPC) patients with documented disease progression:
  • A. If measureable: (RECIST v 1.1) progression;

排除标准

  • 1. Impossibility or unwillingness to take oral drugs;
  • 2. Serious illness or medical unstable condition requiring treatment, symptomatic CNS-metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;

研究者

发起方
Erasmus Medical Center, Daniel den Hoed Cancer Center

相似试验

Studying the influence of budesonide on the exposure... | 临床试验